Skip to main content

Table 6 Comparison of Costs Between Floseal® (Baxter, USA)® and Usual Care

From: Management of Persistent Epistaxis Using Floseal Hemostatic Matrix vs. traditional nasal packing: a prospective randomized control trial

  Control
(N = 13)
Treatment (Floseal)
(N = 13)
Mean Median (IQR) Mean Median (IQR)
Societal erspective Health System Perspective Direct disease-related health services (e.g. physician fees, material costs, admission, surgical fees, medications) $2704.51 (354.71 – 3846.71) $1136.90 (530.11 – 580.92)
Non-Health Sector Costs Work productivity losses (e.g. lost wages) $1342.23 (405.79-1623.16) $676.32 (405.79-405.79)
Total Costs $4046.74 (1033.88-5469.87) $1813.22 (945.10-1164.20)
Differential Mean Costsa (95% CI)b Health system perspective: -$1567.61 (−3787.25 to 652.00)
Societal perspective: - $2233.36 (−5443.27 to 976.56)
  1. a Floseal® (Baxter, USA) minus control
  2. b 95% non-parametric confidence interval based on 1000 bootstrap replications